XML 48 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-based Compensation (Tables)
 12 Months Ended
Dec. 31, 2021
Schedule of Assumptions to Determine Fair Value of Stock Options Awards

The following table summarized the stock option activity and related information under all stock option plans:

 

 

 

Number of
Options

 

 

Weighted-
Average
Exercise
Price

 

 

Weighted-
Average
Remaining
Contractual
Life (Years)

 

 

Aggregate
Intrinsic Value
(in thousands)

 

Outstanding as of January 1, 2019

 

 

5,738,520

 

 

$

0.17

 

 

 

9.01

 

 

$

2,620

 

Granted

 

 

7,089,185

 

 

 

0.29

 

 

 

—

 

 

 

—

 

Exercised

 

 

(243,780

)

 

 

0.14

 

 

 

—

 

 

 

—

 

Forfeited

 

 

(539,751

)

 

 

0.23

 

 

 

—

 

 

 

—

 

Expired

 

 

(130,394

)

 

 

0.24

 

 

 

—

 

 

 

—

 

Outstanding as of December 31, 2019

 

 

11,913,780

 

 

$

0.24

 

 

 

8.73

 

 

$

15,707

 

Granted

 

 

7,393,347

 

 

 

0.55

 

 

 

—

 

 

 

—

 

Exercised

 

 

(351,037

)

 

 

0.20

 

 

 

—

 

 

 

—

 

Forfeited

 

 

(1,006,417

)

 

 

0.40

 

 

 

—

 

 

 

—

 

Expired

 

 

(147,687

)

 

 

0.27

 

 

 

—

 

 

 

—

 

Outstanding as of December 31, 2020

 

 

17,801,986

 

 

$

0.36

 

 

 

8.27

 

 

$

140,560

 

Exercised

 

 

(3,701,243

)

 

 

0.25

 

 

 

—

 

 

 

—

 

Forfeited

 

 

(242,387

)

 

 

0.41

 

 

 

—

 

 

 

—

 

Expired

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Outstanding as of December 31, 2021

 

 

13,858,356

 

 

$

0.39

 

 

 

7.47

 

 

$

99,406

 

Vested and exercisable as of December 31, 2021

 

 

9,678,341

 

 

$

0.33

 

 

 

7.24

 

 

$

69,986

 

Vested and expected to vest as of December 31, 2021

 

 

13,858,356

 

 

$

0.39

 

 

 

7.47

 

 

$

99,406

 
Summary of Stock-Based Compensation Expense

Total stock-based compensation expense by function was as follows (in thousands):

 

 

 

Year ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Cost of Revenue

 

$

1,483

 

 

$

470

 

 

$

32

 

Research and development expenses

 

 

12,754

 

 

 

1,895

 

 

 

1,235

 

Sales and marketing expenses

 

 

371

 

 

 

26

 

 

 

17

 

General and administrative expenses

 

 

7,629

 

 

 

1,415

 

 

 

869

 

Total

 

$

22,237

 

 

$

3,806

 

 

$

2,153

 

 
Restricted Stock [Member]  
Schedule of Restricted Stock Activity

Restricted stock activity for the year ended December 31, 2020 and December 31, 2019 is as follows:

 

 

 

Shares

 

 

Weighted Average
Grant Date Fair
Value per Share

 

Outstanding as of January 1, 2019

 

 

34,878,713

 

 

$

0.03

 

Granted

 

 

—

 

 

 

—

 

Forfeited

 

 

—

 

 

 

—

 

Vested

 

 

(17,439,359

)

 

 

0.03

 

Outstanding as of December 31, 2019

 

 

17,439,354

 

 

$

0.03

 

Granted

 

 

—

 

 

 

—

 

Forfeited

 

 

—

 

 

 

—

 

Vested

 

 

(17,439,354

)

 

 

0.03

 

Outstanding as of December 31, 2020

 

 

—

 

 

$

—

 

There were no restricted stock granted during the years ended December 31, 2021, 2020 and 2019.
Restricted Stock Units (RSUs) [Member]  
Schedule of Stock Options Activity

The following table summarizes our RSU activity (includes performance-based restricted stock units) for the year ended December 31, 2021:

 

 

 

Shares

 

 

Weighted Average
Grant Date Fair
Value per Share

 

Outstanding as of January 1, 2020

 

 

—

 

 

$

—

 

Granted

 

 

1,536,195

 

 

 

7.74

 

Released

 

 

—

 

 

 

—

 

Forfeited

 

 

—

 

 

 

—

 

Outstanding as of December 31, 2020

 

 

1,536,195

 

 

$

7.74

 

Granted

 

 

6,206,975

 

 

 

10.51

 

Released

 

 

(758,945

)

 

 

9.34

 

Forfeited

 

 

(353,146

)

 

 

9.83

 

Outstanding as of December 31, 2021

 

 

6,631,079

 

 

$

10.04